The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized double-blind controlled trial (RCT) of pegfilgrastim as prophylactic therapy in pediatric patients with solid tumors during myelosuppressive chemotherapy.
S. E. Anaya Aguirre
No relevant relationships to disclose
V. Wanzke Del Angel
No relevant relationships to disclose
H. Rivera Marquez
No relevant relationships to disclose
M. Villasis Keever
No relevant relationships to disclose
E. Lopez Aguilar
No relevant relationships to disclose
F. Cerecedo Diaz
No relevant relationships to disclose